Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 9451

Sort by

Sort Order Select

Journal Articles

Long-term treatment of venous thromboembolism

Clive Kearon, Susan R. Kahn

Blood (2020) 135 (5): 317–325.

https://doi.org/10.1182/blood.2019002364

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Blood (2019) 134 (Supplement_1): 1985.

https://doi.org/10.1182/blood-2019-122013

Published: 2019

Journal Articles

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Kendall H Sullivan, PharmD, Michael Toscani, PharmD, Tayla Poretta, PharmD, Ciera Patzke, PharmD, BCOP, Thushara Korattyil, PharmD, Denalee O'Malley, PhD MSW, Victor Gonzalez, MA, MS, Joseph Barone, PharmD, Andrew M. Evens, DO,MSc

Blood (2019) 134 (Supplement_1): 2134.

https://doi.org/10.1182/blood-2019-123459

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

Katia Beider, Valeria Voevoda, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Ivetta Danilesko, MD, Ania Hava Grushchenko-Polaq, Olivia Devillers, Idit Wolf, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 1989.

https://doi.org/10.1182/blood-2019-129619

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity Conditioning Regimens in Children with Very High Risk Acute Lymphoblastic Leukemia (VHR ALL): A Single-Center Experience

Elena Vladimirovna Semenova, MD PhD, Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Tatiana A Bykova, MD PhD, Anna Osipova, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar Barhatov, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris V Afanasyev, MD PhD professor

Blood (2019) 134 (Supplement_1): 2050.

https://doi.org/10.1182/blood-2019-128163

Published: 2019

Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA

Blood (2019) 134 (Supplement_1): 2211.

https://doi.org/10.1182/blood-2019-123743

Published: 2019

Journal Articles

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Marisol Betensky, MDMPH, Ernest Amankwah, PhD, Stephanie Brandal, Allen Everett, MD, Neil A Goldenberg, MD PhD

Blood (2019) 134 (Supplement_1): 2424.

https://doi.org/10.1182/blood-2019-131821

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

Polymorphisms in Inflammatory Genes Modulate the Occurrence of Clinical Complications in Patients with Sickle Cell Disease

Blood (2019) 134 (Supplement_1): 4825.

https://doi.org/10.1182/blood-2019-124218

Published: 2019

Journal Articles

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Shufen Cao, Gouri Dharmavaram, Kirsten M Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Pingfu Fu, Paolo F Caimi, MD

Blood (2019) 134 (Supplement_1): 4770.

https://doi.org/10.1182/blood-2019-131527

Published: 2019

Journal Articles

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Ramon Mohanlal, PhD MD, Douglas W. Blayney, MD, Lan Huang, PhD

Blood (2019) 134 (Supplement_1): 4860.

https://doi.org/10.1182/blood-2019-128563

Published: 2019

Journal Articles

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 4861.

https://doi.org/10.1182/blood-2019-127227

Published: 2019

Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD

Blood (2019) 134 (Supplement_1): 4767.

https://doi.org/10.1182/blood-2019-123688

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

Journal Articles

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Elena Zamagni, MD, Sujith Dhanasiri, Adam Moore, Arun Ghale, Murielle Roussel, MD

Blood (2019) 134 (Supplement_1): 4772.

https://doi.org/10.1182/blood-2019-123629

Published: 2019

Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 4740.

https://doi.org/10.1182/blood-2019-123491

Published: 2019

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

NARROW

Long-term treatment of venous thromboembolism

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity Conditioning Regimens in Children with Very High Risk Acute Lymphoblastic Leukemia (VHR ALL): A Single-Center Experience

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

Polymorphisms in Inflammatory Genes Modulate the Occurrence of Clinical Complications in Patients with Sickle Cell Disease

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only